Ignite Creation Date:
2024-05-05 @ 5:35 PM
Last Modification Date:
2024-10-26 @ 9:33 AM
Study NCT ID:
NCT00486135
Status:
COMPLETED
Last Update Posted:
2013-02-01
First Post:
2007-06-11
Brief Title:
Study of the Safety and Pharmacokinetics of XL147 SAR245408 in Adults With Solid Tumors or Lymphoma
Sponsor:
Sanofi
Organization:
Sanofi
Study Overview
Official Title:
A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of XL147 Administered Orally Daily to Subjects With Solid Tumors or Lymphoma
Status:
COMPLETED
Status Verified Date:
2013-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate the safety and tolerability of XL147 in subjects with solid tumors or lymphoma Both a capsule and a tablet formulation will be evaluated XL147 is a new chemical entity that inhibits PI3 Kinase Inactivation of PI3K has been shown to inhibit growth and induce apoptosis programmed cell death in tumor cells
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| XL147-001 | OTHER | Other study code | None |